drugset / Trial / NCT04964219

Analgesic Effects of Low-dose S-ketamine in Major Spine Fusion Surgery

NCT04964219

Phase 4 Completed 164 enrolled Peking University First Hospital
RandomizedParallel-groupTriple-blindTreatment

Summary

Despite opioid-based multimodal analgesia, moderate-to-severe pain remains a big problem in patients following multi-segment spinal fusion. As a N-methyl-D-aspartate receptor antagonist, S-ketamine has prominent analgesic effects through activating receptors both in the brain and in the spinal cord, inhibiting the excitatory postsynaptic potential, and thus blunting nociception transmission. This randomized controlled trial is designed to investigate whether perioperative S-ketamine infusion can decrease pain intensity after major spine fusion surgery.

Timeline

Start
2022-02-08
Primary completion
2025-04-01
Completion
2025-05-02

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Esketamine Other / unclassified 0.15 mg/kg Intravenous
Subject Esketamine Other / unclassified 25 mg Intravenous

Indications

No indication recorded.